NeurOdys Therapeutics Secures Pre-Seed Funding and to Advance Small Molecule Therapies for Neurodegenerative Diseases
Rambam AG and NLC Health Venture announced the pre-seed funding and launch of NeurOdys Therapeutics.
Rambam AG Executives to Participate in BIO-Europe 2024 in Stockholm
Rambam AG is pleased to announce that Sanja Tomovska, Chief Growth Officer, and Rouslan Michtchenko, Executive Director, will represent the company at BIO-Europe 2024 in Stockholm, Sweden, from November 4 to 6, 2024.
Rambam AG Expands European Presence by Accelerating Polku Therapeutics’ Neurodegenerative Drug Discovery Program
Rambam AG, a European venture studio and part of the Expert Systems accelerator, is expanding its presence in the European biotech landscape through a strategic collaboration with Polku Therapeutics Oy.
Dr. Tudor Oprea and Dr. Ruben Abagyan presented at “Artificial Intelligence for Early Drug Discovery” Conference in San Diego
Dr. Ruben Abagyan presented at the event with a discussion on “Giga-Screening for Preclinical Candidates with a Defined Multi-Target Profile”, where he explored the challenges of rapid identification of first-in-class or best-in-class preclinical drug candidates, illustrating the topic with examples of Eilean Therapeutics’ program for “tough” targets such as FLT3 and BCL2.